905 results about "Cervical ca" patented technology

Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol's iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.

The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to induce strong CD8 T cell response and therefore, are important as sources of antigens for dendritic cell immunotherapy to treat cervical cancer. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of HLA types so that they can be used in concert to develop a preventative vaccine, which can be used for general population.

The invention provides a DNA detection and analysis method based on Cas9 nuclease and application thereof. The method comprises the following three steps: (1) carrying out PCR amplification on targetDNAs; (2) treating a PCR amplification product by using a CAT method; and (3) carrying out PCR amplification with DNAs treated by using the CAT method as a template. The method can successfully detectL1 and E6 / E7 genes of HPV16 and HPV18 in human cervical carcinoma cells. According to the invention, the method successfully avoids current key bottleneck problems in nucleic acid hybridization, designing of specific PCR primers and the like in the fields of nucleic acid detection and typing.

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

The invention relates to a truncated human papillomavirus type 16 L1 protein, virus-like particles composed of the protein, a vaccine containing the virus-like particles, and an application thereof in preventing cervical cancer.

The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.

The invention relates to an electrochemical immunosensor, and in particular relates to a sandwich type electrochemical immunosensor which is constructed by taking Au-hybridized mesoporous carbon CMK-3(Au@CMK-3) and two electronic mediators, namely neutral red and thionine, as second antibody markers, a preparation method of the sandwich type electrochemical immunosensor, and application of the electrochemical immunosensor, which is prepared by the method, to simultaneous detection on markers of a cervical cancer. The electrochemical immunosensor can be used for simultaneously detecting two samples and overcoming the limitation of a single index, plays an important role in further improvement of the early confirming rate of the cervical cancer, and can be popularized to the field of simultaneous detection on tumor markers of other cancers.

The invention relates to a monoclonal antibody of AP‑2alpha and its use in the preparation of medicines for treating cervical cancer. The monoclonal antibody has a good effect of inhibiting the proliferation of cervical cancer cells and has broad application prospects.

The present invention is directed to the examination of the pattern of immunodominant CD8 T cell epitopes in the E6 and E7 protein of Human Papillomavirus (HPV) and its further characterization in terms of its amino acid sequence and HLA restriction. These epitopes are identified based on their ability to induce strong CD8 T cell response and therefore, are important as sources of antigens for dendritic cell immunotherapy to treat cervical cancer. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of HLA types so that they can be used in concert to develop a preventative vaccine, which can be used for general population.

According to the method of evaluating female genital cancer of the present invention, amino acid concentration data on concentration values of amino acids in blood collected from a subject to be evaluated is measured, and the state of female genital cancer including at least one of cervical cancer, endometrial cancer, and ovarian cancer in the subject is evaluated based on the concentration value of at least one of Thr, Ser, Asn, Gln, Pro, Gly, Ala, Cit, Val, Met, Ile, Leu, Tyr, Phe, His, Trp, Orn, Lys, and Arg contained in the measured amino acid concentration data of the subject.

The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof.

The present invention relates to an AP-2alpha monoclonal antibody and an application to preparation of drugs for treating cervical cancers. The monoclonal antibody has the relatively good cervical cancer cell proliferation inhibiting effect, thereby having the wide application prospect.

The invention belongs to the technical field of chemical and pharmaceutical industry and particularly relates to the application of mogrol H9 for preparing antitumor drugs. The invention provides the application of mogrol H9 for preparing antitumor medicaments. The tumor cell can be liver cancer cell, leukaemia cell, cervical carcinoma cell, lung adenocarcinoma cell, stomach cancer cell, breast cancer cell or pancreatic cancer cell. The compound H9 is a natural product, has less toxic and adverse effects, high bioavailability and stable property, and is significant in clinical use. The small molecule compound is developed as a new antitumor drug or antitumor effective component, has an obvious antitumor effect, is green and environment-friendly, and provides a new approach to treatment and healing of tumors.